Nexalin Technology Welcomes Dr. Robert Rothstein to Advisory Board
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW), a pioneer in Deep Intracranial Frequency Stimulation (DIFS™), has made significant strides in addressing the complexities of mental health by appointing Dr. Robert Rothstein to its Scientific Advisory Board (SAB). This move highlights the company’s commitment to combating mental health challenges, particularly concerning Alzheimer’s disease and Traumatic Brain Injury (TBI).
Dr. Rothstein’s Expertise and Its Impact
With an extensive career spanning over four decades, Dr. Rothstein brings a wealth of experience in emergency medicine and mental health innovation. His previous roles at renowned institutions, including the University of Chicago and Johns Hopkins Medicine, have provided him with unique insights that can advance Nexalin’s initiatives in neuropsychiatric therapies. His expertise is crucial as Nexalin prepares for upcoming FDA submissions, ensuring the company is well-equipped for future challenges.
Enhancing Alzheimer’s Treatment Strategies
The appointment of Dr. Rothstein follows Nexalin's renewed dedication to Alzheimer’s research, supported by compelling internal and external studies that signify the potential of DIFS™ to influence brain regions tied to memory and cognitive functions. The company is increasing its focus on developing innovative treatment methodologies aimed at addressing the pressing needs in Alzheimer’s care.
Strategies for Traumatic Brain Injury
Alongside its work in Alzheimer’s, Nexalin is prioritizing research into TBI recovery, particularly for military personnel. Early investigations suggest that DIFS™ may enhance resilience and recovery following brain injuries. The company's goal is to provide effective, non-invasive therapeutic solutions that stand apart from traditional treatment options.
Leadership Perspective on Future Goals
Mark White, CEO of Nexalin Technology, expressed his enthusiasm for adding Dr. Rothstein to the SAB, citing his emergency medicine and mental health management experience as invaluable assets for the company's clinical strategies. With numerous regulatory milestones pending, Dr. Rothstein is expected to play a pivotal role in shaping the direction of Nexalin’s upcoming trials and regulatory engagements.
Innovative Approaches in Neurostimulation
Nexalin’s commitment to developing innovative neurostimulation products is rooted in the company’s mission to confront the global mental health crisis head-on. The focus on non-invasive and patient-friendly approaches is central to Nexalin’s ethos. The Gen-2 15 milliamp neurostimulation device has already received approvals in multiple countries, emphasizing the company's global reach and dedication to delivering effective mental health solutions.
Looking Ahead
With Dr. Rothstein’s addition, Nexalin is strategically positioned to enhance its clinical portfolio. The company is planning to initiate trials specifically for Alzheimer’s treatment later this year, with further TBI research set to follow. This structured approach emphasizes rigorous assessments, utilizing advanced imaging techniques and meticulous supervision from the SAB.
Frequently Asked Questions
What is the role of Dr. Robert Rothstein at Nexalin Technology?
Dr. Robert Rothstein has been appointed to the Scientific Advisory Board to support Nexalin's initiatives in treating Alzheimer’s and Traumatic Brain Injury.
What is Deep Intracranial Frequency Stimulation (DIFS™)?
DIFS™ is a novel neurostimulation approach developed by Nexalin to address various mental health issues through non-invasive techniques.
How does Nexalin's technology assist with Alzheimer’s treatment?
Nexalin’s technology aims to stimulate brain regions involved in memory, potentially offering therapeutic benefits without pharmaceutical side effects.
What is Nexalin's focus on Traumatic Brain Injury?
Nexalin is exploring the application of its therapies for military personnel suffering from TBI, aiming to enhance recovery and resilience.
How can one learn more about Nexalin Technology?
For more information, you can visit Nexalin's official website at https://nexalin.com/.
